Human Anti-IL21R Recombinant Antibody (clone 19F5) (CAT#: HPAB-0247CQ)

Figure 1 Neutralization of IL-21 dependent proliferation of BaF3 cells expressing IL-21R.

Human IL-21R-transfected BaF3 cells were treated with antibodies and human IL-21.

Young, D., & Bloom, L. In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.

Figure 2 Serum concentration-time profiles of Ab following a single 10 mg/kg dose to MRL-Faslpr mice.

Time points at which all animals showed concentration values below the LOQ are indicated by ovals.

Young, D., & Bloom, L. In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.

Figure 3 IgG deposits in the kidneys of MRL-Faslpr mice treated with anti-IL-21R antibodies.

IgG deposits in the kidney sections were assessed by immunohistochemistry and scored blindly on a scale of 0 (none) to 4 (severe) at the 10 week time point.

Young, D., & Bloom, L. In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.

Figure 4 IL-21 overrides Treg-mediated suppression of T effector cytokine production and proliferation.

Data are representative of 2-5 independent experiments.

Lajoie, S., Lewkowich, I., Herman, N. S., Sproles, A., Pesce, J. T., Wynn, T. A., ... & Wills‐Karp, M. (2014). IL‐21 receptor signalling partially mediates Th2‐mediated allergic airway responses. Clinical & Experimental Allergy, 44(7), 976-985.